Skip to main content
Sign In

Hematologic Malignancies Program

Hematologic malignancies represent some of the most aggressive forms of cancer, and in many cases, current therapeutic options are very limited. Thus, the goal of the Hematologic Malignancies (HEME) Program is to define key biological features of leukemia and related blood cancers and translate these findings into more effective therapies for patients.

Scientific Goals

          • Investigate the developmental, genetic and environmental drivers

          • Study metabolic and signaling changes

          • Develop novel therapeutic strategies


A wide variety of clinical trials are available through the Hematologic Malignancies research program. Click here to see which trials are currently enrolling adult participants. For more information click the study identifier or search the identifier number at

For pediatric clinical trials, please call 720-777-6740 or email